Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 12/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 12/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.54 |
| ▸ | PDE4A | P27815 | 6/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11633449 | 0.88 | PDE3B (0.54) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL11149621 | 0.86 | PDE3B (0.57) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL10956470 | 0.86 | PDE3B (0.57) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL11741233 | 0.83 | PDE3B (0.55) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL9687325 | 0.83 | PDE3B (0.55) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL11740487 | 0.83 | SMN1; SMN2 (0.53) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL11740072 | 0.82 | PDE3B (0.57) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL2844401 | 0.82 | PDE3B (0.54) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL9687288 | 0.82 | PDE3B (0.57) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL10961174 | 0.82 | PDE3B (0.54) | PDE3BPDE3APDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ARTESIAN THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ARTESIAN THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ARTESIAN THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| EP-1833480-A2 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | Artesian Therapeutics, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1830852-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006060122-A9 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS INC (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006060122-A9 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS INC (US) | 2006-08-17 | — | — | WO | disclosed |
| US-5135932-A | 2-HYDROXYPROPYLAMINO-ALKYL-BENZIMIDAZOLY-5-YL DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEART DISEASE | DR. KARL THOMAE GMBH (DE) | 1992-08-04 | — | — | US | disclosed |
| US-5100892-A | Hypotensive agents, congestive heart failure | GLAXO INC. (US) | 1992-03-31 | — | — | US | disclosed |
| US-5096904-A | Congestive heart failure | GLAXO INC. (US) | 1992-03-17 | — | — | US | disclosed |
| US-5053338-A | Hydrolysis of ester to obtain an optically enriched mixture of a phenol enantiomer | GLAXO INC. (US) | 1991-10-01 | — | — | US | disclosed |
| EP-0412814-A2 | Pyridazinones having cardiotonic and beta blocking activity | GLAXO WELLCOME INC. (US) | 1991-02-13 | — | — | EP | disclosed |
| US-4914093-A | CARDIOVASCULAR DISORDERS | SANKYO COMPANY LIMITED (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0330242-A1 | Pyridazinone derivatives, their preparation and use | Sankyo Company Limited (JP) | 1989-08-30 | — | — | EP | disclosed |
| EP-0178189-A2 | Pyridazinone derivatives, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
| US-4052395-A | AGRICULTURAL FUNGICIDAL COMPOSITIONS CONTAINING 6-(SUBSTITUTED PHENYL)-PYRIDAZINONES AND SAID PYRIDAZINONES | SANKYO COMPANY LIMITED (JA) | 1977-10-04 | — | — | US | disclosed |
| US-4011321-A | 6-(3-SUBSTITUTED AMINO-2-HYDROXYPROPOXYARYL)-4,5-DIHYDRO-3(2H)-PYRIDAZINONES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ADRB3, PDE3A, PDE3B | PDE3B 3/4885PDE3A 2/4885PDE4B 8/4885 |
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ADRB3, PDE3A, ADRB1 | PDE3B 4/4885PDE3A 2/4885PDE4B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.